SA
NVAX icon

SRH Advisors’s Novavax NVAX Stock Holding History

SRH Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60
Closed -$758 – 290
2024
Q3 		$758 Hold
60
– – ﹤0.01% 280
2024
Q2 		$760 Sell
60
-1,072
-95% -$10.8K ﹤0.01% 285
2024
Q1 		$5.41K Sell
1,132
-700
-38% -$3.25K ﹤0.01% 255
2023
Q4 		$8.79K Buy
1,832
+1,322
+259% +$8.09K ﹤0.01% 220
2023
Q3 		$3.69K Buy
510
+450
+750% +$3.6K ﹤0.01% 258
2023
Q2 		$416 Hold
60
– – ﹤0.01% 288
2023
Q1 		$0 Hold
60
– – ﹤0.01% 294
2022
Q4 		$1K Hold
60
– – ﹤0.01% 290
2022
Q3 		$1K Hold
60
– – ﹤0.01% 305
2022
Q2 		$3K Hold
60
– – ﹤0.01% 282
2022
Q1 		$4K Hold
60
– – ﹤0.01% 277
2021
Q4 		$9K Hold
60
– – 0.01% 224
2021
Q3 		$12K Hold
60
– – 0.01% 204
2021
Q2 		$13K Hold
60
– – 0.02% 199
2021
Q1 		$11K Hold
60
– – 0.02% 203
2020
Q4 		$7K Hold
60
– – 0.01% 222
2020
Q3 		$7K Buy
+60
New +$7.31K 0.01% 205

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SRH Advisors's NVAX Position: Q4 2024 in Review

SRH Advisors sold out of Novavax (NVAX) in Q4 2024, closing a stake of 60 shares — an estimated $758 sold.

SRH Advisors first reported a position in NVAX in Q3 2020 and held it in 17 quarters. The position peaked at $13K in Q2 2021. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

  • SRH Advisors reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
  • SRH Advisors sold 60 Novavax shares in Q4 2024, an estimated $758.
  • SRH Advisors first reported a position in Novavax in Q3 2020 and held it in 17 quarters.
  • SRH Advisors's Novavax position peaked at $13K in Q2 2021.
  • 234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on SRH Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.